Zogenix wins FDA nod for extended-release hydrocodone; UMass researchers jam up nanoparticles with long-term stability;

> Zogenix ($ZGNX) won FDA approval for its extended-release hydrocodone painkiller after a panel of experts said it wanted the administration to hold off. Story

> Researchers at the University of Massachusetts Amherst have kinetically trapped one liquid within another to be stable over a long period of time, a discovery that could have clear implications for drug delivery. More

> Phosphagenics ($PPGNY) welcomed positive Phase I results for its oxymorphone patch for pain management. Release

> Case Western Reserve University researchers accepted a grant from the National Science Foundation to make complex nanoparticles more easily reproducible for manufacturing. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.